- Halozyme's (HALO) HTI-501 significantly improved the appearance of cellulite on patients' skin in a Phase I/II trial, thereby meeting the main goal of the study.
- Halozyme's effect was compared with a control vehicle and with the skin prior to treatment.
- The effect was maintained at three and six months.
- Share are +5.5% premarket. (PR)
From other sites
at 4-traders.com (Mar 23, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 9, 2015)
at Benzinga.com (Jan 8, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs